chemotherapy

You have access
Metronomic Cyclophosphamide With Cisplatin and Bevacizumab for Refractory Anaplastic Ependymoma: A Retrospective Study
XAVIER CHODERLOS DE LACLOS, DIDIER FRAPPAZ, GUIDO AHLE, CHARLOTTE BRONNIMANN, ISABELLE CATRY-THOMAS, ANTHONY JONCOUR, FRANCOIS GHIRINGHELLI and ELODIE VAULEON

Anticancer Research August 2022, 42 (8) 3863-3867; DOI: https://doi.org/10.21873/anticanres.15878
You have access
Biomarker Profiling Revealed Carcinoembryonic Antigen as a Target of Artesunate in a Ductal Breast Cancer Patient
MOHAMED E.M. SAEED, ASSIA I. DRIF and THOMAS EFFERTH

Anticancer Research July 2022, 42 (7) 3483-3494; DOI: https://doi.org/10.21873/anticanres.15835
You have access
Independent Validation of a Risk Stratification Model Predicting Survival in Patients With Metastatic Hormone-sensitive Prostate Cancer
CARSTEN NIEDER and LUKA STANISAVLJEVIC

Anticancer Research July 2022, 42 (7) 3675-3679; DOI: https://doi.org/10.21873/anticanres.15856
You have access
Circulating Tumor Cells Derived from Advanced Hepatocellular Carcinoma Rapidly Develop Resistance to Cytotoxic Chemotherapy
CHIA-HSUN HSIEH, CHAU-TING YEH, YA-HUI HUANG and MING-WEI LAI

Anticancer Research May 2022, 42 (5) 2479-2486; DOI: https://doi.org/10.21873/anticanres.15726
You have access
Chemotherapy-induced Reversion of Mutant RAS to Wild-type RAS in Metastatic Colorectal Cancer
SUMITO SATO, YO MIKAYAMA, MANABU SHIOZAWA, SUGURU NUKADA, KENTA IGUCHI, HIRONAO OKAMOTO, TAKASHI KOHMURA, KEISUKE KAZAMA, KUNIYA TANAKA, TAKASHI OSHIMA and YASUSHI RINO

Anticancer Research May 2022, 42 (5) 2625-2635; DOI: https://doi.org/10.21873/anticanres.15740
Open Access
Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial
KEISHO CHIN, DAISUKE TAKAHARI, RYOHEI KAWABATA, HISASHI HOSAKA, SO SAITOU, TAKESHI SHIRAISHI, HIROSHI YABUSAKI, MASAHIRO GOTO, MASATO NAKAMURA, HIROSHI IMAMURA, YOSHIAKI SHINDO, FUMIO NAGASHIMA, WATARU ICHIKAWA, TAKASHI SAOTOME, WATARU YAMAMOTO, NAOKI ISHIZUKA and KENSEI YAMAGUCHI

Anticancer Research May 2022, 42 (5) 2683-2687; DOI: https://doi.org/10.21873/anticanres.15746
You have access
Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study
KOICHI OKAMOTO, ITASU NINOMIYA, HIROTO SAITO, MARI SHIMADA, TAKAHISA YAMAGUCHI, SHIRO TERAI, HIDEKI MORIYAMA, JUN KINOSHITA, KEISHI NAKAMURA and NORIYUKI INAKI

Anticancer Research May 2022, 42 (5) 2783-2790; DOI: https://doi.org/10.21873/anticanres.15758
You have access
The Trend of Combined Modality Treatment and its Outcomes in Elderly Patients With Primary CNS Lymphoma: A 12-year Population-based Analysis Using Propensity Score
YAZAN SAMHOURI, MOAATH K. MUSTAFA ALI, CYRUS KHAN, RODNEY WEGNER, SEUNG TAE LEE and JOHN LISTER

Anticancer Research April 2022, 42 (4) 1867-1877; DOI: https://doi.org/10.21873/anticanres.15663
You have access
Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?
MARTIN SVATON, MONIKA BRATOVA, LEONA KOUBKOVA, ONDREJ FISCHER, BOHUSLAV MELICHAR, MICHAL HRNCIARIK, DANIEL DOLEZAL, ONDREJ BILEK, JANA KREJCI, MARIE DROSSLEROVA, ZDENKA DLOUHA, JIRI BLAZEK, PETRA MAJKOVA, LUCIE BROZOVA and MAREK STASTNY

Anticancer Research April 2022, 42 (4) 1987-1995; DOI: https://doi.org/10.21873/anticanres.15677
You have access
Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study
ANGIOLO GADDUCCI, STEFANIA COSIO, FABIO LANDONI, ANDREA ALBERTO LISSONI, PAOLO ZOLA, MARIA ELENA LAUDANI, ANTONIO ARDIZZOIA, ANGELA GAMBINO and ENRICO SARTORI

Anticancer Research April 2022, 42 (4) 2017-2022; DOI: https://doi.org/10.21873/anticanres.15681

Main menu

User menu

Search

chemotherapy

Pages